Insilico's 30-candidate pipeline and one patient dataset
Zhavoronkov's 30-candidate count checks out against Insilico's pipeline page and ClinicalTrials.gov, but the most detailed patient data covers 71 people over 12 weeks in a safety-primary trial of rentosertib; Zhavoronkov holds rank 4 among Eternal Search longevity heroes with a score of 42.0.
71 patients with idiopathic pulmonary fibrosis, 12 weeks, highest dose of rentosertib: mean FVC gain of 98.4 ml. The placebo group lost 20.3 ml over the same period. FVC (forced vital capacity) is the volume of air a person can forcefully exhale after a full inhalation; in pulmonary fibrosis, scar tissue stiffens the lungs and that volume falls. This is the most detailed patient-level data Insilico Medicine has published so far.
On 15 June, Insilico published an excerpt from a Bloomberg interview in which Alex Zhavoronkov put specific numbers on his pipeline: 30 development candidates and three Phase II programs, one of them completed. Insilico's pipeline page separately lists 31 preclinical candidates developed since 2021 and 13 IND clearances (regulatory authorizations to begin clinical trials). ClinicalTrials.gov confirms three Phase II entries: two rentosertib trials in idiopathic pulmonary fibrosis (one completed in China, one recruiting in the US) and one ISM5411 trial in ulcerative colitis with 80 patients. The count checks out.
"Three Phase II programs" is three registry entries: two for one molecule (rentosertib) in one disease across two countries, and a third for ISM5411 in ulcerative colitis. Two molecules, two diseases.
In the rentosertib trial, the primary endpoint (the main measure specified in the protocol) was safety. At high doses, some patients discontinued because of diarrhea and signs of liver toxicity. Twelve weeks is short for a chronic scarring disease. Phase III is expected in the second half of 2026; that is where the early signal either holds or breaks.
Zhavoronkov calls this the "pipeline in a product" strategy: aging has no recognized regulatory diagnosis, so you run the trial in fibrosis or inflammatory bowel disease first, where the endpoints are established, then try to direct the same molecule at aging mechanisms. The logic is pragmatic: between "AI found a molecule" and an approved drug lies the full clinical path: chemistry, manufacturing, safety, trial design, statistics. Late-stage trials and licensing deals will decide how many of those 30 candidates reach patients outside a study.
On Eternal Search, Zhavoronkov sits at rank 4 among longevity heroes with a score of 42.0.
Open the related Eternal Search page
Sources
linkedin.com
t.me
The Bloomberg interview gave a rare, registry-verifiable pipeline count from an AI-biotech founder, concrete enough to cross-check and narrow. The Eternal Search hero page for Zhavoronkov (rank 4, score 42.0) provides the analytical frame: the score is held down by clinical stage, which is precisely the tension the dispatch unpacks. The page lets readers monitor whether H2 2026 Phase III data shifts the picture.